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Accepted 10 August 2015; Published online 1 September 2015AbstractObjectives: One recommended use of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach
is supporting quality assessment of evidence of comparisons included within a Cochrane overview of reviews. Within our overview, re-
viewers found that current GRADE guidance was insufficient to make reliable and consistent judgments. To support our ratings, we devel-
oped an algorithm to grade quality of evidence using concrete rules.
Methods: Using a pragmatic, exploratory approach, we explored the challenges of applying GRADE levels of evidence and developed
an algorithm to applying GRADE levels of evidence in a consistent and transparent approach. Our methods involved application of algo-
rithms and formulas to samples of reviews, expert panel discussion, and iterative refinement and revision.
Results: The developed algorithm incorporated four key criteria: number of participants, risk of bias of trials, heterogeneity, and meth-
odological quality of the review. A formula for applying GRADE level of evidence from the number of downgrades assigned by the al-
gorithm was agreed.
Conclusion: Our algorithm which assigns GRADE levels of evidence using a set of concrete rules was successfully applied within our
Cochrane overview. We propose that this methodological approach has implications for assessment of quality of evidence within future
evidence syntheses.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cochrane overviews of reviews (Cochrane overviews)
compile evidence from multiple systematic reviews of in-
terventions into one accessible document [1]. An essential
part of an overview is the assessment of the quality of ev-
idence arising from the included reviews, and the GradingFunding: The Cochrane overview was supported by a project grant
(CZH/4/854) from the Chief Scientist Office (CSO), part of the Scottish
Government Health and Social Care Directorate.
Conflict of interest: None.
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http://dx.doi.org/10.1016/j.jclinepi.2015.08.013
0895-4356/ 2016 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).of Recommendations Assessment, Development and Eval-
uation (GRADE) approach [2,3] is the framework recom-
mended by the Cochrane Handbook to facilitate
transparent rating of quality of evidence [1]. Although prin-
cipally developed for grading recommendations during
guideline development, the GRADE system for assessing
the quality of a body of evidence has gained widespread
use within systematic reviews. Journal of Clinical Epidemi-
ology has previously invited researchers to share their expe-
riences of using GRADE [4].
We have recently published a Cochrane overview of
reviews relating to interventions to improve upper limb
(arm) function after stroke [5]. Within this we identified,
from 40 included systematic reviews, 127 comparisons withess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 We developed an algorithm which provided a set of
concrete rules for grading the quality of evidence
within our Cochrane overview.
 The algorithm enables efficient, transparent, reli-
able grading of quality of evidence.
What this adds to what was known?
 Our experience adds to the debate in the literature
about the advantages and disadvantages of using
concrete rules to apply Grading of Recommenda-
tions Assessment, Development and Evaluation
levels of evidence.
What is the implication and what should change
now?
 We have demonstrated that it is possible to develop
an algorithm based on detailed subjective judgment
of what is most important to a specific body of
evidence.
 This methodological approach has implications for
assessment of quality of evidence within future ev-
idence syntheses, which should build on our work
in this area.
A. Pollock et al. / Journal of Clinrelevant outcomes [5]. We planned to grade the evidence
for each relevant comparison using the GRADE definitions
of high, moderate, low, or very low quality of evidence
[2,68], using definitions of these criteria from published
literature on GRADE [9]. However, Berkman et al. [10]
have previously found poor agreement on grading strength
of evidence within systematic reviews using GRADE, even
among experienced systematic reviewers. Berkman et al.
[10] concluded that more specific guidance was required
to assist reviewers in judging grade of evidence. In contrast
to Balshem et al. [6], who warned that a ‘‘mechanistic
approach’’ would obviate the essential component of sub-
jective judgment, Berkman et al. [10] proposed exploring
the ‘‘advantages and disadvantages of concrete rules for
reaching strength of evidence grades.’’
In this brief report, we share our experience of devel-
oping and applying concrete rules to grading quality of ev-
idence of the 127 comparisons included in our overview
and discuss whether this was an advantageous approach.2. Methods
The methods we used were exploratory, developed iter-
atively and pragmatically, to first explore the challenges ofapplying GRADE levels of evidence, and second, develop a
systematic, consistent, and transparent approach to
applying GRADE to efficiently grade the quality of
evidence within these 127 comparisons.
2.1. Exploration of applying GRADE levels of evidence
We explored the process of applying GRADE levels of
evidence to a sample of four purposively selected reviews,
chosen to reflect a range of different types, format, and
quality of reviews. For the comparisons within these four
reviews, two independent, experienced, reviewers with clin-
ical knowledge relating to the topic assessed risk of bias,
publication bias, indirectness, imprecision, and inconsis-
tency and applied the GRADE levels of evidence based
on their considered judgment. The reviewers first familiar-
ized themselves with published materials relating to best
practices in using the GRADE framework, in particular
the 2011 Journal of Clinical Epidemiology 20-part series
[3]. The applied grades of evidence of the two reviewers
were compared and discussed. No statistical assessment
of agreement between reviewers was carried out, as the
aim of this exercise was simply to explore the application
of GRADE to inform subsequent decisions regarding the
methods we would adopt for the overview.
2.2. Development of the initial algorithm
We used an expert panel approach; the overview author
team and Professor Wiffen, who was invited to share his
methodological expertise and experience relating to Co-
chrane overviews, attended an all-day meeting. We had
substantive discussions over the application of GRADE
criteria, and the reviewers’ perceived challenges associated
with the process. We agreed to develop a set of objective
criteria for determining whether the evidence relating to
each comparison was of high, moderate, low, or very low
quality. The team discussed in depth which objective
criteria were perceived to be most relevant to a judgment
of quality of the particular evidence synthesized within this
overview, and specific objective criteria perceived to sup-
port a judgment of ‘‘high,’’ ‘‘moderate,’’ or ‘‘low’’ were
explored. An initial algorithm for assigning downgrades
to the level of evidence was drafted based on these criteria.
2.3. Testing and refining of algorithm
The initial developed algorithm was applied to a conve-
nience sample (alphabetical selection) of five reviews (con-
taining 43 comparisons) identified for inclusion in the
overview. The assigned level of evidence based on this
initial algorithm was explored and compared to previous,
independently applied, subjective judgments of all over-
view authors. An iterative process, involving discussion be-
tween all overview authors, was then carried out, exploring
the impact of the ‘‘weighting’’ assigned to each of the
criteria included in the algorithm. Discussion and further
Table 1. Key criteria considered to be of most importance to our overview and used to make objective decisions relating to the GRADE level of
evidence within the developed algorithm
Criteria considered important Rationale Further information
1. Number of participants Evidence demonstrates an association
between trial sample size and
treatment effects.
Dechartres et al. [11] found that trials with 1,000 patients or
more had, on average, a treatment effect which was 48%
smaller than trials with less than 50 patients. Furthermore,
Dechartres et al. [12] found that the treatment outcome
estimates from pooled meta-analyses within systematic
reviews were generally larger than the results of a
meta-analysis of the largest trials only, particularly for
subjective outcomes.
2. Risk of bias of trials Assessment of risk of bias of trials is
central to ensuring quality of systematic
reviews [13,14], and trials at high risk of
bias are likely to report exaggerated
effect size [15].
For the body of evidence which we were assessing,
we considered that method of randomization and
blinding of outcome assessor were of the highest
importance in assessing risk of bias.
3. Heterogeneity Statistical measures of heterogeneity within
meta-analyses can reflect inconsistency in
results, and I2 provides a recognized
measure of statistical heterogeneity.
With an I2 greater than 75% potentially being ‘‘considerable’’
[16], we decided that this provided a simple, transparent,
and objective criterion for assessment of inconsistency.
4. Methodological quality
of the review
Methodological quality of the review from
which data are extracted is a key factor
in the quality of evidence.
We had previously assessed quality of each included review
using the AMSTAR [17,18]. Reviewers agreed that questions
relating to (1) a priori research design, (2) search
characteristics, (3) independence of study selection, and (4)
data extraction were of the greatest importance to the
methodological quality of the reviews within this overview,
rather than using the total AMSTAR ‘‘score’’
(see Appendix at www.jclinepi.com for details of
these questions).
Abbreviation: GRADE, Grading of Recommendations Assessment, Development and Evaluation; AMSTAR, the AMSTAR quality assessment tool
[17,18].
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algorithm, judged to assign an appropriate number of
downgrades in response to different objective data.
2.4. Development of formula to assign GRADE level of
evidence
We created and applied four different versions of a for-
mula to assign levels of evidence based on numbers of
downgrades to each of the 43 sample comparisons, and
the resulting levels of evidence were explored and dis-
cussed by the overview authors. Discussion continued until
all authors reached consensus on the number of downgrades
which should equate to the GRADE levels of evidence of
high, moderate, low, and very low.
3. Results
During the exploration of applying GRADE to a sample
of reviews, both reviewers communicated that they felt
there was a great deal of subjectivity involved in the assess-
ment of GRADE levels of evidence and that the GRADE
criteria were poorly defined and difficult to apply. The re-
viewers both recounted that they lacked sufficient guidance
to make judgments confidently, and agreement between re-
viewers on GRADE levels of evidence was inconsistent.
Furthermore, both reviewers independently commented that
their decisions to downgrade the level of evidence werelargely being influenced by objective data that had been
extracted for each comparison. In particular, both reviewers
reported using specific data to inform their decision. These
data commonly included the results of the assessment of
risk of bias (on the Cochrane risk of bias tool), measures
of heterogeneity (e.g., I2), and the volume of evidence
(number of trials and included participants).
To develop the initial algorithm, it was agreed that the
key criteria which were of most importance to our overview
and which should be used to make objective decisions
relating to the GRADE level of evidence were number of
participants; risk of bias of trials, specifically in relation
to randomization and blinded outcome assessment; hetero-
geneity; and methodological quality of the review. The
rationale and supporting evidence for agreement over these
four criteria are provided in Table 1. Table 2 illustrates the
final algorithm which was agreed to be most appropriate for
determining the number of downgrades to levels of evi-
dence in reviews. This algorithm results in a maximum of
six downgrades for each assessed comparison; Table 3
illustrates the agreed formula for applying GRADE level
of evidence from the number of assigned downgrades.4. Discussion
We developed an algorithm which provided a set of con-
crete rules for grading quality of evidence. This algorithm
Table 2. Algorithm for determining ‘‘downgrades’’ to levels of evidence in reviews
Area assessed Imprecision Risk of bias (trial quality) Inconsistency Risk of bias (review quality)
Method of assessment
Number of
participants
within
pooled
analysis
Proportion of participants included
in the pooled analysis judged
to have low ROB for randomization
and observer blinding
Heterogeneity,
assessed by
I2 statistic
Responses to AMSTAR questions
1e4 (covering a priori research
design, search characteristics,
independence of study selection,
and data extraction)
No downgrade
(no serious limitations)
200 75% of participants have low
ROB
I2  75% 4/4 are all ‘‘yes’’ (i.e., low ROB)
Downgrade 1 level
(serious limitations)
100e199 !75% of participants have low
ROB
I2 O 75% 3/4 are ‘‘yes’’ and 1 is ‘‘unclear’’
or ‘‘no’’ on AMSTAR
Downgrade 2 levels
(very serious limitations)
1e99 ! 3/4 are ‘‘yes’’ and remainder
are ‘‘unclear’’ or ‘‘no’’ on
AMSTAR
Notes If ROB for individual trials was not
reported within the review, we
were conservative and assumed
that less than 75% of
participants had low ROB.
If only one trial contributed to
analysis, no downgrade;
if I2 not reported,
assumed to be greater
than 75%.
Abbreviations: ROB, risk of bias; AMSTAR, the AMSTAR quality assessment tool [17,18].
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and with careful consideration of the type of evidence
included with this overview. With limited published guid-
ance to aid decisions, the objective criteria, and the ‘‘cut-
offs’’ within these criteria, were agreed by the overview
team, using an iterative process of exploration and discus-
sion. Undoubtedly, the selection of different methodolog-
ical criteria, and cutoffs within these criteria, will have
impacted on the GRADE levels allocated to evidence
within this overview. However, the ‘‘weightings’’ that our
methods gave to different methodological criteria were
considered in detail by the overview team, and care was
taken to ensure that the resultant objectively determined
GRADE levels reflected overview authors’ more subjective
views of the quality of the evidence.
Application of this algorithm to all 127 comparisons
within our overview enabled us to efficiently compute the
GRADE level of evidence based on objective data extracted
from the included reviews. The algorithm afforded a trans-
parent and reproducible system, which avoided the need
for subjective decision making, and we believe this is a key
strength of our overview. However, we are not advocating
that our specific algorithm is directly applied to the assess-
ment of quality of evidence within other overviews or inTable 3. Formula for applying GRADE level of evidence from number of
downgrades determined using the algorithm
GRADE level of evidence
Number of downgrades
(derived from objective assessment)
High 0 downgrade
Moderate 1 or 2 downgrades
Low 3 or 4 downgrades
Very low 5 or 6 downgrades
Abbreviation: GRADE, Grading of Recommendations Assessment,
Development and Evaluation.the assessment of other bodies of evidence. Rather we argue
that this approach may have direct relevance and implica-
tions to authors of other overviews or those involved in as-
sessing other bodies of evidence. Our algorithm was
developed specifically to reflect what we judged to be impor-
tant to the quality of this particular body of evidence. Both the
criteria we included and the cutoffs we applied were
specificallydone might even argue ‘‘subjectively’’d
selected to reflect our expert opinions and considerations
relating to what we perceived to be high-, moderate-, or
low-quality evidence relating to interventions to improve up-
per limb function after stroke. Thus, although we have been
mechanistic in our application of our algorithm, we were not
mechanistic in its development. The algorithm was devel-
oped based on detailed subjective judgment, informed by
in-depth understanding of the topic area, of what was most
important to the quality of this specific body of evidence.
5. Conclusion
We developed an algorithm, which assigned GRADE
levels of evidence using a set of concrete rules, and suc-
cessfully applied this within our Cochrane overview. Our
algorithm was developed to assess the specific body of ev-
idence synthesized within our overview; however, we
believe that our approach to the application of GRADE
levels of evidence may have widespread applicability. We
propose that this methodological approach has implications
for assessment of quality of evidence within future
evidence syntheses, which will be able to build on our work
in this area.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.08.013.
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